Pacific released a research report on April 9 stating that it gave the Pearl Group (000513.SZ) a buying rating. The main reasons for the rating include: 1) chemical preparations are under pressure, Chinese medicine formulations are growing; 2) reducing costs and increasing efficiency to reduce profits; 3) share repurchases+high dividends to return shareholders. (Mainichi Keizai Shimbun)
太平洋4月9日发布研报称，给予丽珠集团（000513.SZ）买入评级。评级理由主要包括：1）化学制剂承压，中药制剂增长；2）降本增效减少利润下滑；3）股份回购+高分红回报股东。（每日经济新闻）
Pacific released a research report on April 9 stating that it gave the Pearl Group (000513.SZ) a buying rating. The main reasons for the rating include: 1) chemical preparations are under pressure, Chinese medicine formulations are growing; 2) reducing co
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.